» Articles » PMID: 29700705

Imaging Scoring Systems for Preoperative Molecular Diagnoses of Lower-grade Gliomas

Overview
Journal Neurosurg Rev
Specialty Neurosurgery
Date 2018 Apr 28
PMID 29700705
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Recent advance in molecular characterization of gliomas showed that patient prognosis and/or tumor chemosensitivity correlate with certain molecular signatures; however, this information is available only after tumor resection. If molecular information is available by routine radiological examinations, surgical strategy as well as overall treatment strategy could be designed preoperatively.With the aim to establish an imaging scoring system for preoperative diagnosis of molecular status in lower-grade gliomas (WHO grade 2 or 3, LrGGs), we investigated 8 imaging features available on routine CT and MRI in 45 LGGs (discovery cohort) and compared them with the status of 1p/19q codeletion, IDH mutations, and MGMT promoter methylation. The scoring systems were established based on the imaging features significantly associated with each molecular signature, and were tested in the another 52 LrGGs (validation cohort).For prediction of 1p/19q codeletion, the scoring system is composed of calcification, indistinct tumor border on T1, paramagnetic susceptibility effect on T1, and cystic component on FLAIR. For prediction of MGMT promoter methylation, the scoring system is composed of indistinct tumor border, surface localization (FLAIR), and cystic component. The scoring system for prediction of IDH status was not established. The 1p/19q score ≥ 3 showed PPV of 96.2% and specificity of 98.1%, and the MGMT methylation score ≥ 2 showed PPV of 77.4% and specificity of 67.6% in the entire cohort.These scoring systems based on widely available imaging information may help to preoperatively design personalized treatment in patients with LrGG.

Citing Articles

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.

Sasaki H, Kitamura Y, Toda M, Hirose Y, Yoshida K Brain Tumor Pathol. 2024; 41(2):43-49.

PMID: 38564040 DOI: 10.1007/s10014-024-00480-1.


Imaging-Based Versus Pathologic Survival Stratifications of Diffuse Glioma According to the 2021 WHO Classification System.

Lee S, Park J, Park S, Kim Y, Hong C, Kim J Korean J Radiol. 2023; 24(8):772-783.

PMID: 37500578 PMC: 10400365. DOI: 10.3348/kjr.2022.0919.


Advanced multiparametric MRI-based scoring for isocitrate dehydrogenase mutation prediction of gliomas.

Hosur B, Ahuja C, Singla N, Gupta K, Singh P Pol J Radiol. 2022; 87:e626-e634.

PMID: 36532252 PMC: 9749783. DOI: 10.5114/pjr.2022.121549.


Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas.

Lasocki A, Buckland M, Drummond K, Wei H, Xie J, Christie M Neuroradiology. 2022; 64(12):2295-2305.

PMID: 35606654 PMC: 9643259. DOI: 10.1007/s00234-022-02975-0.


Maximum 11C-methionine PET uptake as a prognostic imaging biomarker for newly diagnosed and untreated astrocytic glioma.

Nakajo K, Uda T, Kawashima T, Terakawa Y, Ishibashi K, Tsuyuguchi N Sci Rep. 2022; 12(1):546.

PMID: 35017570 PMC: 8752605. DOI: 10.1038/s41598-021-04216-5.


References
1.
Hirose Y, Aldape K, Takahashi M, Berger M, Feuerstein B . Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. J Mol Diagn. 2001; 3(2):62-7. PMC: 1907353. DOI: 10.1016/S1525-1578(10)60653-8. View

2.
Sasaki H, Zlatescu M, Betensky R, Ino Y, Cairncross J, Louis D . PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis. Am J Pathol. 2001; 159(1):359-67. PMC: 1850425. DOI: 10.1016/S0002-9440(10)61702-6. View

3.
Zlatescu M, TehraniYazdi A, Sasaki H, Megyesi J, Betensky R, Louis D . Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res. 2001; 61(18):6713-5. View

4.
Megyesi J, Kachur E, Lee D, Zlatescu M, Betensky R, Forsyth P . Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 2004; 10(13):4303-6. DOI: 10.1158/1078-0432.CCR-04-0209. View

5.
Walker C, du Plessis D, Fildes D, Haylock B, Husband D, Jenkinson M . Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res. 2004; 10(21):7182-91. DOI: 10.1158/1078-0432.CCR-04-0681. View